270 related articles for article (PubMed ID: 33537170)
1. Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma.
Kato T; Kiyotani K; Tomiyama E; Koh Y; Matsushita M; Hayashi Y; Nakano K; Ishizuya Y; Wang C; Hatano K; Kawashima A; Ujike T; Fujita K; Nonomura N; Uemura M
Oncoimmunology; 2021 Jan; 10(1):1862948. PubMed ID: 33537170
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
Klein S; Ghersi D; Manns MP; Prinz I; Cornberg M; Kraft ARM
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641478
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor.
Ji S; Li J; Chang L; Zhao C; Jia R; Tan Z; Liu R; Zhang Y; Li Y; Yin G; Guan Y; Xia X; Yi X; Xu J
Clin Transl Oncol; 2021 Aug; 23(8):1646-1656. PubMed ID: 33583004
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody.
Nakahara Y; Matsutani T; Igarashi Y; Matsuo N; Himuro H; Saito H; Yamada K; Murotani K; Hoshino T; Azuma K; Sasada T
Cancer Immunol Immunother; 2021 Oct; 70(10):2881-2892. PubMed ID: 33751180
[TBL] [Abstract][Full Text] [Related]
5. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
[TBL] [Abstract][Full Text] [Related]
6. Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors.
John J; Woolaver RA; Popolizio V; Chen SMY; Ge H; Krinsky AL; Vashisht M; Kramer Y; Chen Z; Wang JH
Front Immunol; 2022; 13():992630. PubMed ID: 36330507
[TBL] [Abstract][Full Text] [Related]
7. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Au L; Hatipoglu E; Robert de Massy M; Litchfield K; Beattie G; Rowan A; Schnidrig D; Thompson R; Byrne F; Horswell S; Fotiadis N; Hazell S; Nicol D; Shepherd STC; Fendler A; Mason R; Del Rosario L; Edmonds K; Lingard K; Sarker S; Mangwende M; Carlyle E; Attig J; Joshi K; Uddin I; Becker PD; Sunderland MW; Akarca A; Puccio I; Yang WW; Lund T; Dhillon K; Vasquez MD; Ghorani E; Xu H; Spencer C; López JI; Green A; Mahadeva U; Borg E; Mitchison M; Moore DA; Proctor I; Falzon M; Pickering L; Furness AJS; Reading JL; Salgado R; Marafioti T; Jamal-Hanjani M; ; Kassiotis G; Chain B; Larkin J; Swanton C; Quezada SA; Turajlic S;
Cancer Cell; 2021 Nov; 39(11):1497-1518.e11. PubMed ID: 34715028
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes.
Ge H; Ferris RL; Wang JH
Clin Cancer Res; 2023 Feb; 29(3):647-658. PubMed ID: 36315045
[TBL] [Abstract][Full Text] [Related]
9. Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers.
Li Y; Wang J; Wu L; Li X; Zhang X; Zhang G; Xu S; Sun S; Jiao S
Front Immunol; 2021; 12():649343. PubMed ID: 34163469
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of peripheral T-cell receptor repertoire profiling and individualized nomograms in patients with gastrointestinal cancer treated with anti-programmed death 1 antibody.
Wu J; Yu Y; Zhang S; Zhang P; Yu S; Li W; Wang Y; Li Q; Lu B; Chen L; Luo C; Peng H; Liu T; Cui Y
Transl Gastroenterol Hepatol; 2024; 9():5. PubMed ID: 38317746
[TBL] [Abstract][Full Text] [Related]
11. Greater extent of blood-tumor TCR repertoire overlap is associated with favorable clinical responses to PD-1 blockade.
Aoki H; Ueha S; Nakamura Y; Shichino S; Nakajima H; Shimomura M; Sato A; Nakatsura T; Yoshino T; Matsushima K
Cancer Sci; 2021 Aug; 112(8):2993-3004. PubMed ID: 34014607
[TBL] [Abstract][Full Text] [Related]
12. Host-specific differences in top-expanded TCR clonotypes correlate with divergent outcomes of anti-PD-L1 treatment in responders versus non-responders.
John J; Chen SMY; Woolaver RA; Ge H; Vashisht M; Huang Z; Chen Z; Wang JH
Front Immunol; 2023; 14():1100520. PubMed ID: 37051229
[TBL] [Abstract][Full Text] [Related]
13. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade.
Yan C; Ma X; Guo Z; Wei X; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao G; Gao X; Wang T; Jiang Y; Wang P; Pang Q; Zhang W
Oncoimmunology; 2022; 11(1):2025668. PubMed ID: 35036077
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood.
Carlisle JW; Jansen CS; Cardenas MA; Sobierajska E; Reyes AM; Greenwald R; Del Balzo L; Prokhnevska N; Kucuk O; Carthon BC; Mullane PC; Osunkoya A; Baumgarten D; Hosseinzadeh F; Wilkinson S; Lake R; Sowalsky AG; Liu Y; Master VA; Bilen MA; Kissick H
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35863822
[TBL] [Abstract][Full Text] [Related]
15. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
Snyder A; Nathanson T; Funt SA; Ahuja A; Buros Novik J; Hellmann MD; Chang E; Aksoy BA; Al-Ahmadie H; Yusko E; Vignali M; Benzeno S; Boyd M; Moran M; Iyer G; Robins HS; Mardis ER; Merghoub T; Hammerbacher J; Rosenberg JE; Bajorin DF
PLoS Med; 2017 May; 14(5):e1002309. PubMed ID: 28552987
[TBL] [Abstract][Full Text] [Related]
16. Abundant cytomegalovirus (CMV) reactive clonotypes in the CD8(+) T cell receptor alpha repertoire following allogeneic transplantation.
Link CS; Eugster A; Heidenreich F; Rücker-Braun E; Schmiedgen M; Oelschlägel U; Kühn D; Dietz S; Fuchs Y; Dahl A; Domingues AM; Klesse C; Schmitz M; Ehninger G; Bornhäuser M; Schetelig J; Bonifacio E
Clin Exp Immunol; 2016 Jun; 184(3):389-402. PubMed ID: 26800118
[TBL] [Abstract][Full Text] [Related]
17. T Cell Receptor Diversity and Lineage Relationship between Virus-Specific CD8 T Cell Subsets during Chronic Lymphocytic Choriomeningitis Virus Infection.
Chang YM; Wieland A; Li ZR; Im SJ; McGuire DJ; Kissick HT; Antia R; Ahmed R
J Virol; 2020 Sep; 94(20):. PubMed ID: 32759317
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses.
Kidman J; Principe N; Watson M; Lassmann T; Holt RA; Nowak AK; Lesterhuis WJ; Lake RA; Chee J
Front Immunol; 2020; 11():587014. PubMed ID: 33163002
[TBL] [Abstract][Full Text] [Related]
19. TCR Repertoire as a Novel Indicator for Immune Monitoring and Prognosis Assessment of Patients With Cervical Cancer.
Cui JH; Lin KR; Yuan SH; Jin YB; Chen XP; Su XK; Jiang J; Pan YM; Mao SL; Mao XF; Luo W
Front Immunol; 2018; 9():2729. PubMed ID: 30524447
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive investigation of T and B cell receptor repertoires in an MC38 tumor model following murine anti‑PD‑1 administration.
Zhang L; Wang IM; Solban N; Cristescu R; Zeng G; Long B
Mol Med Rep; 2020 Aug; 22(2):975-985. PubMed ID: 32468004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
